Hi there.

I would like your opinion on rebalancing my portfolio. So far I have been a bit haphazard, which I would like to change more and more.

Some individual positions are definitely too large and others too small (due to bonuses in TR or bad buys).

I would now like to build up the core:

• $VHYL (+0,48%)
• 
  $XSX6 (+0,09%)
• and a third ETF (?)

Keep and run as a savings plan in any case $ALV (+0,82%) and $O (-0,41%).

I still find the following interesting $NVDA (+0,36%) and $AAPL (+0,21%) -> but I would probably have to reduce the individual positions?

$BTC (-1%) I would potentially hold and combine with $EWG2 (+0,26%) as satellites in the future.

I'm rather unsure about the other positions - I'd rather wait for the exit, but I would most likely keep $BNTX (+1,36%)

Please don't be too harsh on my portfolio 🙈 I'm aware that I've made some mistakes ...

Hello everyone,

Today I would like to briefly explain why I currently consider BioNTech $BNTX (+1,36%) is currently an interesting buy candidate. The share has recently been under heavy pressure, but in my view it offers an attractive risk/reward ratio, especially for medium to long-term investors.

1. fundamental valuation

• The market capitalization is currently (as of July 2025) significantly below the level of the pandemic peak times, although the company continues to generate solid sales.
• BioNTech has a very strong balance sheet with over € 15 bn in cash, which provides enormous financial flexibility.
• The company has no significant debt, which is a clear advantage given the current interest rate environment.

2. pipeline & future prospects

• BioNTech has consistently invested the proceeds from the Covid vaccines in research and development.
• The cancer immunotherapy pipeline is particularly exciting with several mRNA-based approaches in clinical phases, especially in cooperation with Roche and Genentech.
• BioNTech is also making progress in the area of mRNA vaccines against other infectious diseases (e.g. malaria, tuberculosis, influenza).
• The mRNA technology continues to be regarded as a key platform for rapid, targeted therapy developments.

3. partnerships & strategic orientation

• Collaborations with major players such as Pfizer and Genentech secure know-how, sales power and financial resources.
• Expansion of production capacities, particularly in Africa, strengthens global presence and could open up additional markets in the future.

4. valuation & market psychology

• The share is currently trading at a significant discount to its 2021 high.
• Many investors have "written off" BioNTech after the pandemic, which opens up potential from an anti-cyclical perspective.
• If only some of the cancer therapy programs are successful, this could result in significant revaluations.

Conclusion:

It may remain volatile in the short term, but in the medium to long term I see BioNTech as an exciting biotech stock with substance, an innovative pipeline and a solid financial cushion. The risk/reward ratio appears attractive - especially for investors who are patient and continue to see mRNA as a technology of the future.

I look forward to hearing your opinions - who else is invested here or is watching BioNTech?

Quick question, how do you deal with this, for example, you have a company that you want to restructure but it is slightly in the red in my case $BNTX (+1,36%) and $PYPL (-0,62%) which are both about 5-15% in the red. Wait until they go up or sell now with a minus. I do believe that the two will recover the minus in an uncertain time, but do I want to wait?

$UNH (+0,15%)
$NOVO B (-0,72%)
$HIMS (+2,02%)
$LLY (+1,96%)
$M2PW34
$BNTX (+1,36%)
$OSCR

As every Sunday, the most important news from the past week, as well as the most important dates for the coming week.

Also as a video:

https://youtube.com/shorts/Qnq0Hgw02ok?si=c1DdZaCBPcjb9KK5

Monday:

The Japanese economy contracted slightly less than feared in the first quarter. However, there is still a risk of recession. The annualized figure was only 0.2 % instead of 0.7 %.

https://www.wsj.com/economy/japans-economy-at-risk-of-technical-recession-revised-data-shows-dde9dd61

Wednesday:

The tariffs have hardly had any impact on US inflation so far, but the inflation rate has nevertheless risen to 2.4%. Both core inflation and actual inflation were 10 basis points below expectations, with housing costs being the strongest driver of inflation.

https://www.handelsblatt.com/finanzen/geldpolitik/inflation-us-teuerung-zieht-im-mai-leicht-an/100134062.html

Thursday:

Tragic accident in India with a $BA (-0,28%) Boeing aircraft. Unfortunately, accidents involving Boeing aircraft occur at regular intervals. The cause of the crash remains unclear for the time being.

https://www.spiegel.de/panorama/indien-air-india-maschine-verunglueckt-laut-medienberichten-nahe-flughafen-von-ahmedabad-a-ee140462-a413-4911-b3d1-718864754f55

The Mainz-based biotech company $BNTX (+1,36%) Biontech looks set to buy Tübingen-based competitor $CVAC (-0,22%) Curevac. Curevac is valued at around 1 billion euros. The German government is thus making a loss of around 130 million euros on its investment in Curevac, proving once again why the state is not a good investor.

https://www.focus.de/finanzen/biontech-will-deutschen-konkurrenten-curevac-uebernehmen_af5d792a-c419-4fed-b23b-4f8573d1620b.html

Friday:

Isreal's attack on Iran had been looming since yesterday. Negotiations with the USA on ending the nuclear weapons program stalled. Trump had embassy staff in Iraq withdrawn yesterday.

https://m.bild.de/politik/israel-greift-iran-an-explosionen-im-raum-teheran-684b71ab8858611e27641106

These are the most important dates for the coming week:

Wednesday: 20:00 Interest rate decision (USA)

Thursday: 13:00 Interest rate decision (UK)

Friday: 01:30 BoJ meeting minutes (Japan)

#japan
#usa
#bip
#inflation
#erzeugerpreise

SAP $SAP (+1,3%) is being targeted by the German Federal Cartel Office, which has recently launched an investigation into the acquisition of Signavio. This measure is a reaction to the accusations made by competitor Celonis, which accuses SAP of alleged misconduct. In 2021, the software giant acquired Signavio for almost one billion euros, which was approved by the regulatory authorities at the time. Signavio was a direct competitor of Celonis, and the ongoing investigations could have a lasting impact not only on the acquisition but also on SAP's entire market position. The industry is watching with interest to see how the situation will develop and what consequences this could have for SAP.

In another major move, Biontech $BNTX (+1,36%) announced the acquisition of Curevac $CVAC (-0,22%) which is seen as a significant step forward for the company. According to a pharmaceutical executive close to owners Thomas and Andreas Strüngmann, this deal reflects the strength of Biontech. At the important conference of the American Society of Clinical Oncology (ASCO) at the end of May, Biontech presented promising results that further fueled interest in the company. As part of the takeover, Curevac shares are to be exchanged for Biontech depositary receipts, which catapulted the Curevac share price up to 28 percent. As a result, the market capitalization returned to the level of the beginning of the year. Nevertheless, the valuation of Curevac shares remains 95% below the 2020 records, which shows how volatile the market for biopharmaceutical companies is.

Sources:

https://www.manager-magazin.de/unternehmen/tech/sap-bundeskartellamt-untersucht-signavio-uebernahme-nach-celonis-vorwuerfen-a-0c00eeae-8c0c-41d1-a698-c4cf526bf8c2

https://www.manager-magazin.de/unternehmen/pharma/biontech-uebernimmt-curevac-was-steckt-hinter-dem-milliarden-deal-a-e147eb69-8847-480a-8c8c-8ffab2947c7f

$BNTX (+1,36%)

https://www.n-tv.de/newsletter/breakingnews/Biontech-will-deutschen-Konkurrenten-Curevac-uebernehmen-article25829589.html

$BNTX (+1,36%) Now I know.

https://www.ariva.de/news/milliardenschwere-kooperation-von-biontech-und-us-konzern-11652162

Good evening everyone, as I won't be here much tomorrow, I've decided to send you the second part today. I'm devoting myself to one of my favorite, but generally not very widespread species of derivatives, namely the Inline OS. There is no long or short here, as they are suitable for sideways phases.

With inline OSs such as the one shown here, there is a range within which the underlying must move over the entire term. If the upper or lower limit is breached, the bond expires worthless. However, if it remains within the range for the entire term, the bill is always redeemed at € 10 at the end. The bill below is based on the €/SFR rate (0.92/0.97) and runs until June 5, i.e. 2 weeks. I bought it at €1.90 when it was quite close to the lower limit. I mostly trade currency pairs or oil with these bills. Stocks also work, but I would only take large stocks. At the moment I have one on $BNTX (+1,36%) and on $RHM (-0,71%) . Smaller, more market-oriented stocks can easily be pushed over the barrier by the issuer if they are close to one of the limits. That's why I stay away from them.

So the topic is relatively easy to deal with. Nevertheless, I hope it has been informative for you. If you have any questions about this very interesting product, please feel free to ask.

I wish you all a pleasant evening.